April 1, 1999British Journal of PharmacologyOpen Access

UK‐78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage‐gated potassium channel and inhibits human T cell activation

View Full Paper

Ask AI

Bookmark

Population

In vitro models including Kv1.3 voltage-gated potassium channels and human T-lymphocytes

Comparison

UK-78,282 (a novel piperidine compound) vs CP-190,325, verapamil, tetraethylammonium, and…

Design

Preclinical

Authors

DHDouglas C. HansonThe University of Texas at San Antonio ANAngela NguyenUniversity of California, Irvine RMRobert J. MatherPfizer (United States)

Discussion

Member takes

Implication

May support Kv1.3 as a drug target; leaves open translation to in vivo immunomodulation or clinical use.

Structured PICO

Population

In vitro models including Kv1.3 voltage-gated potassium channels and human T-lymphocytes

Intervention

UK-78,282 (a novel piperidine compound)

Comparator

CP-190,325 (related compound), verapamil, tetraethylammonium, and charybdotoxin (in competition/comparison assays)

Outcome

Kv1.3 channel blockade (IC50) and suppression of human T-lymphocyte activationsurrogate

UK-78,282 is a potent, use-dependent blocker of the Kv1.3 channel that suppresses human T-cell activation, suggesting potential as an immunomodulatory agent.

Cite This Study

Hanson et al. (1999) studied this question.

synapsesocial.com/papers/6a70a2c745e51b8c202729cf https://doi.org/10.1038/sj.bjp.0702480

View Full Paper

Ask AI

Bookmark

UK‐78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage‐gated potassium channel and inhibits human T cell activation

Discussion

Member takes

Implication

Structured PICO

Cite This Study

UK‐78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage‐gated potassium channel and inhibits human T cell activation

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider